Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 13;5(1):55-60.
doi: 10.1002/jha2.828. eCollection 2024 Feb.

Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study

Kamel Laribi  1 , Xavier Leleu  2 , Nathalie Texier  3 , Raphaël Germain  3 , Cyrille Touzeau  4 , Mohammad Hammoud  5 , Alexandre Payssot  6 , Samantha Schulmann  7 , Ronan Le Calloch  8 , Adrien Trebouet  9 , Driss Chaoui  10 , Selva David  11 , Omar Benbrahim  12 , Riad Benramdane  13 , Anne Charvet-Rumpler  14 , Christelle Jadeau  15 , Eglantine Rouanet  15 , Olivier Decaux  16 , Aurore Perrot  17
Affiliations

Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study

Kamel Laribi et al. EJHaem. .

Abstract

The real-life retrospective observational study CARMYN aimed at investigating the long-term efficacy and safety of carfilzomib in combination with dexamethasone and lenalidomide (KRd, 159 patients). These patients (62% in first and 38% in second relapse, median age 62 yo) were treated between 02/2014 and 02/2017. Most had been pre-exposed to bortezomib (98.2%) and to an IMID (75.4%). At the time of collection, 90% had permanently discontinued carfilzomib. Data collection was conducted from January to July 2021 in 27 participating sites, after a median of 39 months follow-up. For patients treated with KRd, an overall response rate of 78.4% translated in a median progression free survival (PFS) of 24.0 months (95% CI 18.8-27.6) and a median overall survival (OS) of 51.1 months (95% CI 41.3-not reached). Results were poorer but difficult to interpret in the small cohort of Kd recipients. The study is one of the longest real-life studies of carfilzomib treatment in patients in first or second relapse. CARMYN confirmed the real-life long-term efficacy of carfilzomib in combination with lenalidomide and dexamethasone with results similar to those of clinical trials. The KRd regimen is thus an option to consider for late relapses in the current context of MM management.

Keywords: carfilzomib; effectiveness; real‐life evidence; refractory relapsing multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

KL received honoraria from AbbVie, AstraZeneca, Beigene, Iqone, Janssen, Novartis and Takeda. XL is a consultant and received honoraria from Amgen, Merck, BMS, GSK, Janssen, Oncopeptide, Takeda, Roche, Novartis, AbbVie, Sanofi, Gilead, Pfizer, Harpoon Therapeutic, Regeneron and Iteos. CT received adboards and honoraria from AMGEN. RLC received honoraria from Abbvie, Gilead, Takeda and Janssen.DC received honoraria from Roche. AP received honoraria from Abbvie, Amgen, BMS, Janssen, Pfizer, Sanofi & Takeda. The other authors declare no financial interests.

Figures

FIGURE 1
FIGURE 1
Progression free survival (PFS). Patients treated in second (blue) or third (red) line of therapy.
FIGURE 2
FIGURE 2
Overall survival (OS). Patients treated in second (blue) or third (red) line of therapy.
See this image and copyright information in PMC

References

    1. Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22:5419–5427. - PMC - PubMed
    1. Cavo M, Terpos E, Bargay J, Einsele H, Cavet J, Greil R, et al. The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. Expert Rev Hematol. 2018;11:219–237. - PubMed
    1. Goldschmidt H, Ashcroft J, Szabo Z, Garderet L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol. 2019;98:1–18. - PMC - PubMed
    1. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA‐ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2021;32:309–322. - PubMed
    1. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152. - PubMed

LinkOut - more resources